Oxford University Press

SHERPA: Yellow

People

  1. De Angelis
    De Angelis
  2. Drilon
    Drilon
  3. Motzer
    Motzer
  4. Mellinghoff
    Mellinghoff
  5. Rosenblum
    Rosenblum
  6. Shuman
    Shuman
  7. Dunkel
    Dunkel
  8. Karajannis
    Karajannis
  9. Saltz
    Saltz
  10. Souweidane
    Souweidane

Groups

  1. Department of Medicine (1983)
  2. Solid Tumor Oncology Division (1615)
  3. GSK Faculty (761)
  4. Survivorship Research (635)
  5. Population Sciences Research Program (612)
  6. Epidemiology and Biostatistics (463)
  7. Department of Pathology and Laboratory Medicine (412)
  8. Gastrointestinal Oncology Service (385)
  9. Genitourinary Oncology Service (364)
  10. Tow Center for Developmental Oncology (TCDO) (352)
Search Within
Formats
  1. Journal Article (2092)
  2. Meeting Abstract (2072)
  3. Book Section (179)
  4. Review (88)
  5. Editorial (80)
  6. Guidelines (35)
  7. Correspondence (24)
  8. Book Whole (17)
  9. Conference Paper (15)
  10. Research Letter (9)
Groups
  1. Department of Medicine (1983)
  2. Solid Tumor Oncology Division (1615)
  3. GSK Faculty (761)
  4. Survivorship Research (635)
  5. Population Sciences Research Program (612)
  6. Epidemiology and Biostatistics (463)

More Groups

People
  1. Lisa De Angelis (119)
  2. Alexander Drilon (108)
  3. Robert Motzer (96)
  4. Ingo Mellinghoff (93)
  5. Marc Rosenblum (87)
  6. Stewart Shuman (87)

More People

Years
  1. 2025 (64)
  2. 2024 (304)
  3. 2023 (320)
  4. 2022 (331)
  5. 2021 (323)
  6. 2020 (325)

More Years

Publications
  1. Annals of Oncology (1666)
  2. Neuro-Oncology (845)
  3. JNCI: Journal of the National Cancer Institute (482)
  4. Nucleic Acids Research (209)
  5. Clinical Infectious Diseases (138)
  6. American Journal of Clinical Pathology (105)

More Publications

Results (4611)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Safety, efficacy, and patient-reported outcomes (PROs) with vimseltinib in patients (pts) with tenosynovial giant cell tumor (TGCT) who received prior antiecolony-stimulating factor 1 (CSF1) therapy: Ongoing phase II study
    Meeting Abstract

    D'Amato, G.; Wagner, A. J.; Ganjoo, K. N.; Stacchiotti, S.; Gelderblom, H.; Ryan, C. W.; Palmerini, E.; Ravi, V.; Saleh, R.; Le Cesne, A.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Role of PIK3CA as a predictive biomarker in metastatic, imatinib-resistant GIST: A ct-DNA substudy of the VOYAGER trial
    Meeting Abstract

    Schardt, L. A.; Serrano, C.; Trent, J. C.; Krzeciesa, D.; Newberry, K.; Grassian, A.; Kang, Y. K.; Rutkowski, P.; Jones, R. L.; Heinrich, M.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Utility of circulating tumor DNA (ctDNA) as a molecular biomarker in the phase II trial of imatinib plus binimetinib in patients with treatment-naïve, advanced gastrointestinal stromal tumor (GIST)
    Meeting Abstract

    Kelly, C. M.; Bradic, M.; Saunds, S.; Avutu, V.; Chan, J.; D'Angelo, S. P.; Dickson, M.; Gounder, M.; Keohan, M. L.; Movva, S.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • A retrospective single-center study of outcomes to immune checkpoint blockade-based therapy in leiomyosarcoma
    Meeting Abstract

    Babatunde, O.; Rosenbaum, E.; Kelly, C. M.; Desir-Camille, R.; Keohan, M. L.; Banks, L.; Avutu, V.; Chan, J.; Reed, D.; Gounder, M.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • SAABR: Single arm phase II study of androgen receptor pathway inhibitor (ARPI) + atezolizumab + GnRH analog (ADT) and stereotactic body radiotherapy (SBRT) to the prostate in men with de novo hormone-sensitive metastatic prostate cancer (mHSPC)
    Meeting Abstract

    Rathkopf, D.; Dallos, M.; Stein, M.; Spina, C. S.; Deutsch, I.; Nguyen, C.; Okada, A.; Lloyd, M.; Manarite, J.; McBride, S.
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Avelumab + axitinib (Ave + Axi) vs sunitinib (Sun) in advanced renal cell carcinoma (aRCC): Final analysis of patient (pt)-reported outcomes (PROs) and quality-adjusted time without symptoms or toxicity (Q-TWiST)
    Meeting Abstract

    Venugopal, B.; Choueiri, T. K.; Penkov, K. D.; Albiges, L.; Uemura, H.; Larkin, J.; Tomita, Y.; Wang, J.; Hoffman, J.; Gerhold-Ay, A.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • An open label phase IIa study evaluating the preliminary efficacy of intratumoural tigilanol tiglate (TT) in advanced and/or metastatic soft tissue sarcoma (STS)
    Meeting Abstract

    Bartlett, E. K.; Li, D.; Shemla, S.; Ariyan, C. E.; Dickinson, S.; Crago, A.; Li, G.; Agaram, N.; D'Angelo, S. P.; Maki, R. G.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • A phase II study of palbociclib combined with the PD-1 inhibitor retifanlimab in patients with advanced dedifferentiated liposarcoma
    Meeting Abstract

    Rosenbaum, E.; Qin, L. X.; Dickson, M.; Movva, S.; Kelly, C. M.; Chan, J.; Chi, P.; Banks, L.; Keohan, M. L.; Gounder, M.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Validation of automated bone scan index as a progression endpoint in two phase III studies of metastatic castration resistant prostate cancer (mCRPC) patients
    Meeting Abstract

    Knezevic, A.; Heller, G.; Sjöstrand, K.; Anand, A.; Borzillo, G.; Larson, S.; Morris, M. J.
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Phase I/II trial of oral masofaniten (EPI-7386) in combination with enzalutamide (Enz) compared to enz alone in metastatic castration-resistant prostate cancer (mCRPC) subjects
    Meeting Abstract

    Kyriakopoulos, C.; Chatta, G.; Laccetti, A. L.; Iannotti, N.; Sokolova, A. O.; Hotte, S. J.; Tutrone, R.; Markowski, M. C.; Nordquist, L. T.; Pili, R.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save